非小细胞肺癌市场：按类型,疗法（化疗,靶向疗法（贝伐单抗,Necitumumab,雷莫芦单抗）,免疫疗法）,用户,地区-规模,份额,前景,机会分析2022-2030

肺癌的症状在早期可能不明显，因为它们可能是其他疾病的症状，例如肺炎或肺萎陷。肺癌的症状包括胸痛、呼吸困难、喘息、体重减轻、持续咳嗽、声音嘶哑或变声、呼吸急促以及支气管炎和肺炎等肺部问题。此外，当它通过血液和淋巴扩散到身体其他部位时，就会出现骨痛、四肢无力、皮肤发黄、眼睛发黄、头痛和抽搐等症状。

肺癌的诊断可能涉及诊断成像，例如 X 光、MRI、超声和 CT，以及痰细胞学，通过吐出痰来检查是否存在癌细胞。我有。此外，通过细针穿刺活检、支气管镜、纵隔镜等方法采集肺部异常增生和肺水肿的肺细胞，可诊断肺癌。

市场动态

在预测期内，非小细胞肺癌预计将成为市场增长的驱动力，这在很大程度上是由烟草消费增加和被动吸烟增加推动的。例如，根据2022年3月公布的数据，美国疾病控制与预防中心（CDC）估计，每年约有4000万美国成年人吸食香烟，估计有255万中学生每年至少使用一支电子烟. 它声明它使用一种烟草产品。

这项研究的主要特点

• 本报告对全球非小细胞肺癌治疗市场进行了深入分析，显示了以 2021 年为基数的预测期（2022-2030 年）的市场规模和復合年增长率 (CAGR%)年。
• 它揭示了不同细分市场的潜在收入机会，并为该市场概述了一个有吸引力的投资建议矩阵。
• 它还提供了有关市场驱动因素、制约因素、机会、新产品发布和批准、市场趋势、区域前景以及主要参与者采用的竞争战略的重要见解。
• 根据公司亮点、产品组合、主要亮点、财务业绩和战略等参数对全球非小细胞肺癌市场的主要参与者进行了概况分析。
• 本研究涵盖的主要公司包括辉瑞公司、阿斯利康公司、F. Hoffmann-La Roche Ltd.、Eli Lilly and Company、Boehringer Ingelheim GMBH、Novartis AG、Bristol-Myers Squibb Company 和 Merck & Co ., 公司
• 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
• 《全球非小细胞肺癌疗法市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者将能够通过用于分析全球非小细胞肺癌市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第二章市场展望

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 市场概况：按类型分类
  • 市场概况：按疗法分类
  • 市场概况：按最终用户分类
  • 市场概况：按地区
• 连贯机会图 (COM)

第3章市场动态、规律及趋势分析

• 市场动态
  • 司机
  • 约束因素
  • 市场机会
• 影响分析
• 市场趋势
• 近期趋势
• 收购和合作场景
• 技术概览
• 监管情景
• 管道分析
• 害虫分析

第 4 章全球非小细胞肺癌治疗市场 - COVID-19 影响分析

• 总体影响
• 对供需的影响
• COVID-19 对市场的影响

第 5 章全球非小细胞肺癌治疗市场类型，2017-2030

• 腺癌
• 鳞状细胞癌
• 大细胞癌
• 大细胞神经内分泌肿瘤

第 6 章全球非小细胞肺癌治疗市场（按疗法）：2017-2030

• 化疗
• 靶向治疗
• 贝伐珠单抗（阿瓦斯汀）
• Necitumumab（Portorazza）
• 雷莫芦单抗（Cyramza）
• 免疫疗法
• 纳武单抗 (Opdivo)
• Atezolizumab（Tecentriq）
• 其他

第 7 章全球非小细胞肺癌治疗市场：按最终用户分类，2017-2030

• 医院
• 家庭护理
• 专科诊所
• 其他

第 8 章全球非小细胞肺癌治疗市场：地区，2017-2030

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 英国
• 德国
• 意大利
• 法国
• 西班牙
• 俄罗斯
• 其他欧洲
• 亚太地区
• 中国
• 印度
• 日本
• 东盟
• 澳大利亚
• 韩国
• 其他亚太地区
• 中东
• 海湾合作委员会
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中非
• 南非

第9章竞争格局

• Pfizer Inc.
• AstraZeneca plc
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Boehringer Ingelheim GMBH
• Novartis AG
• Bristol-Myers Squibb Company
• Merck & Co., Inc.

第 10 章

• 调查方法
• 关于出版商

Lung cancer symptoms are not noticeable in its early stage as these symptoms are considered for other type of illness such as pneumonia or collapsed lung. Some symptoms of lung cancer include chest pain, harsh/raspy sound while breathing, wheezing, weight loss, continuous cough, hoarseness or voice changes, shortness of breath, lung problems such as bronchitis or pneumonia, and others. Moreover, if it spreads through the bloodstream or the lymphatics into other parts of the body then it exhibits symptoms such as bone pain, weakness in arm or leg, yellow skin, yellow eyes, headache, and seizures.

Some diagnostic tests are performed by doctors to detect lung cancer, which include diagnostic imaging tests such as X-ray, magnetic resonance imaging (MRI), ultrasound, computed tomography scan (CT scan), and also by diagnosing mucous, which the patient can cough up to check the presence of cancer cells, which is called as sputum cytology. By taking the cells of lungs from abnormal growth area of the lung or from the fluid of lungs through the procedure called as fine needle aspiration biopsy, bronchoscopy, and mediastinoscopy, lung cancer can be diagnosed.

Market Dynamics

Increasing consumption of tobacco and active engagement in passive smoking are two major factors responsible for non-small cell lung cancer, which are expected to drive market growth over the forecast period. For instance, according to data published in March 2022, on The Centers for Disease Control and Prevention (CDC), stated that nearly 40 million U.S. adults smoke cigarettes, and an estimated 2.55 million middle and high school students use at least one tobacco product, including e-cigarettes every year.

Key features of the study:

• This report provides in-depth analysis of the global non-small cell lung cancer treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global non-small cell lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global non-small cell lung cancer treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-small cell lung cancer market

Detailed Segmentation:

• Global Non-small Cell Lung Cancer Treatment Market, By Type:
  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Large Cell Neuroendocrine Tumors
• Global Non-small Cell Lung Cancer Treatment Market, By Treatment:
  • Chemotherapy
  • Targeted Therapy
    • Bevacizumab (Avastin)
    • Necitumumab (Portrazza)
    • Ramucirumab (Cyramza)
  • Immunotherapy
    • Nivolumab (Opdivo)
    • Atezolizumab (Tecentriq)
  • Others
• Global Non-small Cell Lung Cancer Treatment Market, By End User:
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
• Global Non-small Cell Lung Cancer Treatment Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Pfizer Inc.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AstraZeneca plc
  • Hoffmann-La Roche Ltd.
  • Eli Lilly and Company,
  • Boehringer Ingelheim GMBH
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Treatment
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Technology Overview
• Regulatory Scenario
• Pipeline Analysis
• PEST Analysis

4. Global Non-small Cell Lung Cancer Treatment Market- COVID-19 Impact Analysis

• Overall Impact
• Impact on Supply and Demand
• COVID-19 Impact on the market

5. Global Non-small Cell Lung Cancer Treatment Market, By Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Adenocarcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Squamous Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Large Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Large Cell Neuroendocrine Tumors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Non-small Cell Lung Cancer Treatment Market, By Treatment, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Chemotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Targeted Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Bevacizumab (Avastin)
• Necitumumab (Portrazza)
• Ramucirumab (Cyramza)
• Immunotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Nivolumab (Opdivo)
• Atezolizumab (Tecentriq)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Non-small Cell Lung Cancer Treatment Market, By End User, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospitals
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Homecare
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Specialty Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Non-small Cell Lung Cancer Treatment Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca plc
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• F. Hoffmann-La Roche Ltd.
  • Company Highlights
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Boehringer Ingelheim GMBH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us